SEC Tracker
Get the app
LNAI · XBRL financial data

Lunai Bioworks financial statements, every quarter

The same tables from 15 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (LNAI's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025†Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Revenue——————————2131*
Gross profit——————————21—
Research and development5676211,087435*390161—year only244616(62)*
General and administrative8,2903,6167,6524,999*5,3014,3534,2254,001*2,4111,7661,4212,202*
Total operating expenses8,8844,27051,38117,104*53,3394,5464,162126,919*3,3081,8231,4482,170*
Operating income (loss)(8,884)(4,270)(51,381)(17,104)*(53,339)(4,546)(4,162)(126,919)*(3,308)(1,823)(1,477)(2,139)*
Interest expense179275304253*25099189188*122122108(117)*
Income tax expense (benefit)———year only———year only———year only
Net income (loss)(9,175)(4,529)(58,990)(15,732)*(44,212)(7,252)189(126,732)*2,819(1,799)(2,571)(2,011)*
Earnings per share, basic USD per share(0.14)(0.07)(0.54)—(0.28)(0.04)0.00—0.13(0.08)(0.10)—
Earnings per share, diluted USD per share(0.14)(0.07)(0.54)—(0.28)(0.04)0.00—0.13(0.08)(0.10)—
Weighted average shares, basic thousands of shares64,48165,852109,250—0161,825162,335—22,52023,48324,994—
Weighted average shares, diluted thousands of shares64,48165,852109,250—0161,825163,930—22,52023,48324,994—
  • † Share count changed about 1/10 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/7 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (LNAI's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025†Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Cash and cash equivalents523244313220221312923936254923,1551,714
Accounts receivable——————964—————
Prepaid and other current assets———6694851,269943—————
Total current assets1,9062,4031,2201,9981,9481,7083,6681,0478005143,7332,036
Property and equipment, net48349748948245242239336812131312
Right-of-use asset8648131,3861,2701,1501,181992687————
Goodwill11,64011,640164,187159,330118,171107,999112,6425,9635,9635,9635,9635,963
Total assets57,56358,018178,089163,129121,833111,340117,7268,2316,9616,6669,8619,942
Accrued liabilities7987843,7555,3115,3595,5125,7165,8434,8694,9274,9135,019
Total current liabilities10,09613,75820,87430,31023,03528,60728,84229,15619,72220,00219,28318,910
Lease liability, non-current72166497084271067449842527921413156
Total liabilities10,81614,42343,68431,15223,74629,28129,33929,58120,00120,21519,41418,967
Accumulated deficit(253,204)(257,733)(316,723)(332,455)(376,667)(383,920)(383,730)(510,463)(507,644)(509,443)(512,014)(514,025)
Total stockholders' equity46,74643,596134,406131,97798,08782,05988,387(21,350)(13,041)(13,549)(9,553)(9,025)
Total liabilities and equity57,56358,018178,089163,129121,833111,340117,7268,2316,9616,6669,8619,942
Common shares outstanding (cover page) thousands of shares66,698143,668147,505156,194158,717158,718172,119231,80223,43224,18736,2715,034
  • † Share count changed about 1/10 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/7 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (LNAI's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025†Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Net income (loss)(9,175)(4,529)(58,990)(15,732)*(44,212)(7,252)189(126,732)*2,819(1,799)(2,571)(2,011)*
Stock-based compensation9849991,862828*3585591,499898*181129169151*
Depreciation and amortization27333031*32323233*42111130*
Net cash from operating activities(2,777)(3,147)*(2,634)*(2,414)*(2,016)(2,560)*(1,487)*(1,811)*(1,349)(1,071)*(1,027)*(1,841)*
Purchases of property and equipment——5*24*——————0*0*
Net cash from investing activities(1,058)(57)*(92)*(53)*0——964*545(1)*0*0*
Net cash from financing activities2,5632,847*2,641*2,467*2,0292,591*3,584*178*1,343950*3,704*395*
Net change in cash(1,351)(279)*69*(92)*091*611*(830)*532(133)*2,664*(1,442)*
  • † Share count changed about 1/10 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/7 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Lunai Bioworks1,71431*(1,841)*5.0M0.9 quarters 10-KJun 30, 2026
Dare Bioscience12,618188(6,775)*15.3M1.9 quarters 10-QJun 30, 2026
Imunon6,864not reported(3,025)*5.6M2.3 quarters 10-QJun 30, 2026
Armata Pharmaceuticals23,952not reported(8,666)*37.2M2.8 quarters 10-QJun 30, 2026
Fibrogen50,644(1,474)(3,991)*4.0M22.9 quarters 10-QJun 30, 2026
Aptose Biosciences1,020not reported(5,841)2.6M0.2 quarters 10-QMar 31, 2026
Ovid Therapeutics11,327733(17,594)*195.3M6.7 quarters 10-QJun 30, 2026
vTv Therapeutics86,6430(11,443)*not reported7.6 quarters 10-QJun 30, 2026
Marimed8,43741,9252,219*403.0M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.